 He has been a member of the steering committees of important clinical trials, including the International Studies of Infarct Survival, ISIS2, ISIS3, ISIS4, and the EU funded trials of the European Secondary Prevention Study Group and, furthermore, a national co-ordinator of HOPE and GUARDIAN.He has extensive experience in clinical research.In recent years his main scientific interest has been pharmacotherapy and pharmacoepidemiology of cardiovascular diseases, particularly management of myocardial infarction.